The invention generally relates to analyzing yeast viability. More particularly, the invention relates to efficient and effective methods and compositions for accessing and measuring viability and concentration of yeast cells.

Disclosed herein are methods and compositions useful for identification of potential therapeutic agents for the treatment of a NF1- or RAS-associated disorder. Disclosed herein are also methods and compositions useful for the treatment of a NF1- or RAS-associated disorder.

The invention deals with chromogenic media which are suitable for the selective growth and identification of one or more species of yeast. The subject of the invention is the method that enables us to identify and determine the cell count of Brettanomyces/Dekkera and Zygosaccharomyces yeasts. Besides, the subjects of invention are also the use of the method in wine and/or food industry and the stocks for conducting the experiment.

The invention is directed to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.

The invention is directed to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.

Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula

##STR00001##

are described that are beneficial in treating, for example, diseases and conditions such as Friedreich's ataxia, normal aging, and various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Furthermore, such compounds are useful as probes for identifying defects in mitochondrial metabolism, mitochondrial iron accumulation, cellular stress among other mitochondrial diseases and helping to identify compounds active in overcoming such defects.

Compositions and methods for displaying antibodies in the periplasmic space of yeast cells are disclosed. In particular, antibodies are linked to a cell membrane-spanning transmembrane domain, a cell-membrane associated protein domain that is on the external face of the yeast cell membrane, a protein that binds to the inner face of the yeast cell wall, or a periplasmic protein in order to display the antibodies in the yeast periplasmic space. In addition, a target protein of interest can be coexpressed in yeast such that it is localized to the plasma membrane or periplasmic space and accessible to binding by displayed antibodies. The disclosure further relates to high-throughput screening of antibody libraries using yeast cell periplasmic display.

Provided herein are quality control substances for use with a microscopy-based urine sediment analyzer. The quality control substances comprise a urine matrix and a cancer cell, an algae cell, a yeast cell, egg white, or any combination thereof. Methods of detecting the presence of an analyte in a urine sample from a subject, quality control substances for use in identifying the presence of one or more analytes in a urine sample from a subject, and the use of a cancer cell, an algae cell, a yeast cell, egg white, or any combination thereof in the manufacture of a quality control substance for use with a microscopy-based urine analyzer are also provided.

The method for particle analysis includes a first magnetic susceptibility measurement step S4 of measuring a volume magnetic susceptibility of each of first particles p1; an encapsulation treatment step S5 of performing an encapsulation treatment so that the first particles p1 encapsulate an encapsulation target component pt smaller than the first particles p1; a second magnetic susceptibility measurement step S8 of measuring a volume magnetic susceptibility of each of second particles p2 as an analysis target that are the first particles p1 after the encapsulation treatment; and a step S9 of analyzing whether or not the encapsulation target component pt is encapsulated in the second particles p2 based on a result of measurement in the first magnetic susceptibility measurement step S4 and a result of measurement in the second magnetic susceptibility measurement step S8.

Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula ##STR00001##
are described that are beneficial in treating, for example, diseases and conditions such as Friedreich's ataxia, normal aging, and various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Furthermore, such compounds are useful as probes for identifying defects in mitochondrial metabolism, mitochondrial iron accumulation, cellular stress among other mitochondrial diseases and helping to identify compounds active in overcoming such defects.